Jun 22, 2020
Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas
Jun 18, 2020
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera(TM) MRD Testing
Jun 17, 2020
Natera Files Patent Suit Against Progenity, Inc.
Jun 01, 2020
Natera Launches Quantification Technique to Enhance Prospera(TM) Test Precision; Initiates PEDAL Study for New Insights
May 26, 2020
Natera Announces New Prospera(TM) Data at ATC Showcasing Innovation in Cell-Free DNA
May 19, 2020
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
May 13, 2020
Natera to Present at the UBS Virtual Global Healthcare Conference
May 04, 2020
Natera Announces Achievement of Key Recruitment Milestones in ProActive Study and Success in Prospera(TM) Early Access Program
Apr 15, 2020
Natera Asserts Three New Oncology Patents Against ArcherDX
Apr 13, 2020
Natera Announces Preliminary First Quarter 2020 Financial Results
Mar 03, 2020
Natera to Participate in Upcoming Investor Conferences
Mar 03, 2020
Natera Receives Favorable Medicare Reimbursement Pricing for Prospera(TM)
Feb 26, 2020
Natera Reports Fourth Quarter and Year 2019 Financial Results
Feb 19, 2020
Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call
Feb 18, 2020
Natera Files False Advertising Counterclaim Against CareDx
Jan 27, 2020
Natera Files Suit Against ArcherDX for Patent Infringement
Jan 15, 2020
National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera(TM) MRD Testing in Stage II-III Colorectal Cancer
Jan 09, 2020
Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera(TM) Patients with Stage II-III Colorectal Cancer
Jan 06, 2020
Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents
Dec 19, 2019
Natera Receives Final Medicare Coverage for Prospera(TM) Organ Transplant Rejection Assessment Test